On the other hand, a monotherapy with sitagliptin and combination therapy with sitagliptin and a sulfonylurea agent for 12 weeks significantly decreased FABP4 concentration in patients with type 2 diabetes [23]. The gene discussed is FABP4; the disease is type 2 diabetes mellitus.